- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00199238
Efficacy of Rupatadine 5, 10 and 20 mg in Chronic Idiopathic Urticaria
A 4-week Dose-finding, Multicentre, Double-blind, Randomised, Placebo-controlled, Parallel-group Trial to Assess the Efficacy and Safety of Different Doses of Rupatadine Compared to Placebo in the Treatment of Chronic Idiopathic Urticaria
Study Overview
Detailed Description
Objectives: To evaluate the efficacy and safety of rupatadine for the treatment of CIU symptoms.To assess the clinical efficacy of a dose ranging of rupatadine fumarate (5mg, 10mg, and 20 mg) compared with placebo for relief of CIU symptoms.
Methodology: A dose-finding multicentre, double-blind, randomised, placebo-controlled, parallel-group study Number of patients (planned and analysed): 248 patients. 62 patients will be allocated to each treatment group. 283 patients were randomised and analysed.
Diagnosis and criteria for inclusion: Man or woman aged between 12 and 65. Documented history of active CIU (urticaria wheals) with or without an associated angioedema for at least three days per week over the last 6 weeks prior to Day 0 . Active CIU (score ³2 labelled as moderate pruritus) for at least 3 days (not necessarily consecutive days) in the week before inclusion with a total score of active CIU ³6 labelled as moderate pruritus for these 3 days. Results of standard laboratory biochemistry and haematology tests obtained at screening within acceptable limits as assessed by investigator. Patient who signed the informed consent form.
Test product, dose, mode of administration, batch N°: Rupatadine 5,10 and 20 mg tablets; oral dose of 1 tablet/day for 4 consecutive weeks; batch 0102 (France) and batch 0203 (Hungary, Romania and Argentina). Expiry date: 12/2003 (France) and 10/2004 (Hungary, Romania and Argentina).
Duration of treatment: Oral administration of test formulation (5, 10, 20 mg) or placebo daily, for 4 consecutive weeks.
Reference therapy: Placebo tablets, 1 tablet/day for 4 consecutive weeks. Criteria for evaluation (efficacy): Primary efficacy measure of each treatment will compare the frequency and severity of symptoms of CIU as measured by the patient in terms of change in mean pruritus score (MPS) over the 4-week treatment period.Secondary efficacy measures include change from baseline over the 4-week treatment period in the mean number of wheals (MNW) score; mean total symptoms score (MTSS), calculated as the sum of the MPS (Mean pruritus symptoms) and the MNW (Mean number of wheals) scores and the interference with sleep and daily activities due to urticaria symptoms Criteria for evaluation (safety): AEs, laboratory tests and vital signs
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Paris Cedex 10, France, 75475
- Hospital Saint Louis
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Man or woman aged between 12 and 65
- Documented history of active CIU (urticaria wheals) with or without an associated angioedema for at least three days per week over the last 6 weeks prior to Day 0
- Active CIU (score ³2 labelled as moderate pruritus) for at least 3 days (not necessarily consecutive days) in the week before inclusion with a total score of active CIU ³6 labelled as moderate pruritus for these 3 days
- Results of standard laboratory biochemistry and haematology tests obtained at screening within acceptable limits as assessed by investigator
- Patient who signed the informed consent form -
Exclusion Criteria:
- CIU associated to some underlying disease (Hodgkin's disease/vasculitis/lupus erythematous/hepatitis)
Patient under any systemic or topical medication for CIU and/or an inferior wash-out period as stated as follows:
- H1-receptor antagonists: fexofenadine (10 days prior to Day 0), loratadine, cetirizine, hydroxyzine, diphenhydramine, cyproheptadine, etc. (3 days prior to Day 0)
- H2-receptor antagonists: cimetidine, ranitidine and famotidine (2 days prior to Day 0)
- H1- and H2-receptor antagonists: doxepin (7 days prior to Day 0)
- Leukotriene antagonists: zafirlukast and montelukast (4 days prior to Day 0)
- Corticosteroids: prednisone and methylprednisolone (7 days prior to Day 0)
- Tricyclic antidepressants: imipramin and amitriptilin (30 days prior to Day 0)
The informed consent form must be signed prior to any washout period is set up.
- Physical urticaria due to cold, heat, and/or sun
- Cholinergic urticaria
- Patient taking any potential inhibitors of the CYP3A4 isozyme of cytochrome P450 such as ketoconazole, erythromycin and/or tricyclic antidepressants, e.g. imipramin, amitriptilin, etc.
- Urticaria due to known aetiology (e.g., medications, insects bites, food, etc)
- Patient unresponsive to antihistaminic treatment
- Patient with psychiatric disorders, vascular, hepatic, neurological, endocrine or other major systemic disease
- Pregnant or lactating female
- Patient with any heart abnormality of clinical relevance or any pathological changes of the heart rate
- Patient under any medication which could interfere with drug effect or with interpretation of efficacy parameters
- Subject handling dangerous machinery or driving as an integral part of his/her occupation
- Patient with hereditary angioedema or isolated dermographism
- Patient with disease caused by a parasite
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
Once daily/ 28 days
|
Other Names:
|
Experimental: rupatadine 5mg
Once daily/ 28 days
|
Other Names:
|
Experimental: rupatadine 10 mg
Once daily/ 28 days
|
Other Names:
|
Experimental: rupatadine 20 mg
Once daily/ 28 days
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pruritus
Time Frame: 4 weeks
|
change in mean pruritus score (MPS) over the 4-week treatment period.
|
4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Wheals
Time Frame: 4 weeks
|
change in mean number of wheals score (MNW) over the 4-week treatment period.
|
4 weeks
|
change in mean total symptoms score (MTSS) over the 4-week treatment period.
Time Frame: 4 weeks
|
4 weeks
|
|
overall impression
Time Frame: 4 weeks
|
overall impression for efficacy was done by the investigator and by the patient
|
4 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: EVA ARNAIZ, PhD, J. Uriach y Compañía
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2002/47
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on URTICARIA
-
Marcus MaurerCompletedNon-autoreactive Chronic Spontaneous Urticaria | Autoimmune Chronic Spontaneous Urticaria | Autoreactive, Non-autoimmune Chronic Spontaneous UrticariaGermany
-
United BioPharmaCompleted
-
University Hospital, LilleRecruitingSpontaneous Urticaria, ChronicFrance
-
United BioPharmaNot yet recruiting
-
Johns Hopkins UniversityNational Institute of Allergy and Infectious Diseases (NIAID)CompletedUrticaria ChronicUnited States
-
Novartis PharmaceuticalsCompletedCHRONIC SPONTANEOUS URTICARIAFrance
-
University Hospital Inselspital, BerneNovartis; University of Bern; Adverse Drug Reactions, Advice and Consulting ADR-ACCompletedChronic Idiopathic Urticaria | Chronic Urticaria | Chronic Spontaneous UrticariaSwitzerland
-
Novartis PharmaceuticalsTerminatedChronic Spontaneous Urticaria | Cold Urticaria | Cholinergic UrticariaGermany
-
United BioPharmaRecruiting
-
Second Xiangya Hospital of Central South UniversityNot yet recruitingChronic Spontaneous UrticariaChina
Clinical Trials on Rupatadine Fumarate
-
J. Uriach and CompanyUnknown
-
Charite University, Berlin, GermanyTerminated
-
J. Uriach and CompanyTerminated
-
J. Uriach and CompanyCompleted
-
Swiss Federal Institute of TechnologyUniversity of Zurich; University Children's Hospital, Zurich; Jomo Kenyatta University...CompletedAnemia, Iron-deficiencyKenya
-
University Of PerugiaUnknownUrinary Tract Infection
-
Xi'an Xintong Pharmaceutical Research Co.,Ltd.Unknown
-
Swiss Federal Institute of TechnologyCompletedIron-deficiencySwitzerland
-
Geron CorporationCompletedMultiple MyelomaUnited States
-
University Health Network, TorontoActive, not recruitingAcute Myeloid Leukemia | Myelodysplastic Syndromes | Relapsed Cancer | Refractory CancerCanada